Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Psychopharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF00179180PMID 3097715
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Viloxazine: A Review of Its Pharmacological Properties and Therapeutic Efficacy in Depressive Illness

  2012cited by this paper
• Pharmacokinetics of viloxazine hydrochloride in man

  2010cited by this paper
• Age-related differences in kinetics and side-effects of viloxazine in man and their clinical implications

  2004cited by this paper
• Anticonvulsant and proconvulsant properties of viloxazine hydrochloride: Pharmacological and pharmacokinetic studies in rodents and the epileptic baboon

  2004cited by this paper
• Carbamazepine-viloxazine interaction in patients with epilepsy.

  1986cited by this paper
• PHARMACOKINETIC INTERACTIONS BETWEEN ANTIEPILEPTIC AND PSYCHOTROPIC DRUGS

  1984cited by this paper
• A Sensitive Gas Chromatographic Assay for the Determination of Serum Viloxazine Concentration Using a Nitrogen‐Phosphorus‐Selective Detector

  1984cited by this paper
• Effect of Viloxazine on Serum Carbamazepine Levels in Epileptic Patients

  1984cited by this paper
• A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients.

  1984cited by this paper
• Does viloxazine have epileptogenic properties?

  1984cited by this paper
• Stereospecificity of behavioural effects of viloxazine in bulbectomized rats does not correlate with its 5‐HT‐releasing action in vitro

  1982cited by this paper
• Pharmacokinetic Interactions with Antiepileptic Drugs

  1982cited by this paper
• Clinical pharmacology of viloxazine hydrochloride.

  1981cited by this paper
• Viloxazine: a review of the literature.

  1980cited by this paper
• The disposition and metabolism of I.C.I. 58,834 (viloxazine) in humans.

  1975cited by this paper
• Blood level studies with viloxazine hydrochloride in man.

  1975cited by this paper

• Viloxazine extended-release capsules as an emerging treatment for attention-deficit/hyperactivity disorder in children and adolescents

  2024cites this paper
• Viloxazine for the Treatment of Attention Deficit Hyperactivity Disorder.

  2022cites this paper
• Population Pharmacokinetics of Viloxazine Extended‐Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder

  2021cites this paper
• Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status

  2021cites this paper
• Clinically Significant Drug–Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder

  2019cites this paper
• Clinical Significance of Pharmacokinetic Interactions Between Antiepileptic and Psychotropic Drugs

  2002cites this paper
• Erratum: Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure–activity relationship (QSAR) with the Abraham descriptors*

  2002cites this paper
• Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors.

  2001cites this paper
• Pharmacokinetic drug interactions. Part 3: Drugs P-Z.

  1995cites this paper
• Comparative Tolerability Profiles of the Newer versus Older Antidepressants

  1994cites this paper
• Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy

  1994cites this paper
• Effects of administration route on pharmacokinetics of viloxazine in the rabbit.

  1992cites this paper
• Elevation of plasma phenytoin by viloxazine in epileptic patients: a clinically significant drug interaction.

  1992cites this paper
• The absolute oral bioavailability of selected drugs.

  1989cites this paper